Miguélez M, Velasco C, Camblor M, Cedeño J, Serrano C, Bretón I, Arhip L, Motilla M, Carrascal M L, Olivares P, Morales A, Brox N, Cuerda C
Nutrition Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Nutrition Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Clin Nutr. 2022 Dec;41(12):2940-2946. doi: 10.1016/j.clnu.2021.10.020. Epub 2021 Nov 1.
BACKGROUND & AIMS: Severe COVID-19 infection is characterized by an inflammatory response and lung injury that can evolve into an acute respiratory distress syndrome that needs support treatment in intensive care unit. Nutritional treatment is an important component of the management of critically ill patients and should be started in the first 48 h of ICU admission to avoid malnutrition. This study describes the characteristics of the patients treated in a tertiary hospital in Madrid during the months of March-May 2020 (first wave), the medical nutrition treatment employed and its influence in the clinical outcome of these patients.
This is a retrospective study including COVID-19 patients admitted in ICU that needed medical nutrition treatment (MNT). Collected variables included sex, age, BMI, underlying diseases, time from hospitalisation to ICU admission, type of respiratory support (invasive mechanical ventilation (IMV) or high flow nasal cannula (HFNC) or non-invasive ventilation (non-IMV)), caloric and protein requirements (25 kcal/kg adjusted body weight (ABW), 1.3 g/kg ABW/day), MNT type (enteral nutrition (EN), parenteral nutrition (PN), mixed EN + PN), total calories (including propofol) and proteins administered, percentage of caloric and protein goal in ICU day 4th and 7th, metabolic complications, acute kidney failure (AKF), length of stay (LOS) and mortality. Data are expressed as mean ± SD, median (IQR) or frequencies. Statistical analysis was performed with the IBM SPSS Statistics for Windows, Version 25.0. p < 0.05 were considered statistically significant.
A total of 176 patients were included (72.7% male), 60.1 ± 13.5 years, BMI 29.9 ± 5.4 kg/m. Underlying diseases included 47.4% overweight, 39.8% obesity, 49.1% hypertension, 41.4% dyslipidaemia. 88.6% of patients needed IMV, 89.1% prone position, 2.9% ECMO. Time to ICU admission: 2 (4.75) days. Estimated caloric and protein requirements were 1775 ± 202 kcal and 92.4 ± 10.3 g. Calories and proteins administered at days 4th and 7th were 1425 ± 577 kcal and 66 ± 26 g and 1574 ± 555 and 74 ± 37, respectively. Most of the patients received PN (alone or complementary to EN) to cover nutritional requirements (82.4% at day 4th and 77.9% at day 7th). IVM patients received more calories and proteins during the first week of ICU admission. Complications included 77.8% hyperglycaemia, 13.2% hypoglycaemia, 83.8% hypertriglyceridemia, and 35.1% AKF. ICU LOS was 20.5 (26) days. The mortality rate was 36.4%.
In our series, the majority of patients reached energy and protein requirements in the first week of ICU admission due to the use of PN (total or complementary to EN). Patients with HFNC or non-IMV may be at risk of malnutrition if total or complementary PN to oral diet/ONS/tube feeding is not used to cover nutritional requirements. Therefore, if EN is not possible or insufficient, PN can be safely used in critically ill patients with COVID-19 with a close monitoring of metabolic complications.
重症新型冠状病毒肺炎(COVID-19)感染的特征是炎症反应和肺损伤,可发展为急性呼吸窘迫综合征,需要在重症监护病房进行支持治疗。营养治疗是危重症患者管理的重要组成部分,应在入住重症监护病房的头48小时内开始,以避免营养不良。本研究描述了2020年3月至5月(第一波疫情期间)在马德里一家三级医院接受治疗的患者的特征、采用的医学营养治疗及其对这些患者临床结局的影响。
这是一项回顾性研究,纳入了入住重症监护病房且需要医学营养治疗(MNT)的COVID-19患者。收集的变量包括性别、年龄、体重指数(BMI)、基础疾病、从住院到入住重症监护病房的时间、呼吸支持类型(有创机械通气(IMV)或高流量鼻导管吸氧(HFNC)或无创通气(非IMV))、热量和蛋白质需求(25千卡/千克调整体重(ABW),1.3克/千克ABW/天)、MNT类型(肠内营养(EN)、肠外营养(PN)、EN+PN混合)、给予的总热量(包括丙泊酚)和蛋白质、入住重症监护病房第4天和第7天热量和蛋白质目标的达成百分比、代谢并发症、急性肾衰竭(AKF)、住院时间(LOS)和死亡率。数据以平均值±标准差、中位数(四分位间距)或频率表示。使用IBM SPSS Statistics for Windows 25.0版进行统计分析。p<0.05被认为具有统计学意义。
共纳入176例患者(72.7%为男性),年龄60.1±13.5岁,BMI为29.9±5.4千克/米²。基础疾病包括47.4%超重、39.8%肥胖、49.1%高血压、41.4%血脂异常。88.6%的患者需要IMV,89.1%需要俯卧位通气,2.9%需要体外膜肺氧合(ECMO)。入住重症监护病房的时间:2(4.75)天。估计的热量和蛋白质需求分别为1775±202千卡和92.4±10.3克。第4天和第7天给予的热量和蛋白质分别为1425±577千卡和66±26克以及1574±555千卡和74±37克。大多数患者接受PN(单独或与EN互补)以满足营养需求(第4天为82.4%,第7天为77.9%)。接受IMV的患者在入住重症监护病房的第一周接受了更多的热量和蛋白质。并发症包括77.8%高血糖、13.2%低血糖、83.8%高甘油三酯血症和35.1%AKF。重症监护病房住院时间为20.5(26)天。死亡率为36.4%。
在我们的研究系列中,由于使用PN(全部或与EN互补),大多数患者在入住重症监护病房的第一周达到了能量和蛋白质需求。如果不使用全部或与口服饮食/口服营养补充剂/管饲互补的PN来满足营养需求,HFNC或非IMV患者可能存在营养不良风险。因此,如果无法进行EN或EN不足,可以在密切监测代谢并发症的情况下,将PN安全地用于重症COVID-19患者。